More than a month after the launch of the new iPLEDGE Risk Evaluation and Mitigation Strategy (REMS) program, the operation still isn't running smoothly for many dermatologists, pharmacists, and ...
In December 2021, major changes took effect in the iPLEDGE program, the US Food and Drug Administration (FDA)–required safety program for managing the risks of isotretinoin's teratogenicity and ...
Please provide your email address to receive an email when new articles are posted on . Researchers, along with the American Academy of Dermatology, have organized an iPLEDGE Workgroup to advocate for ...
Please provide your email address to receive an email when new articles are posted on . Pregnancies, abortions and fetal defects associated with isotretinoin exposure continue to be a problem even ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results